



This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT- $\beta$  receptor)activating agents where at least one LT- $\beta$  receptor activating agent is an anti-LT- $\beta$  receptor antibody.

# REPORT